Sportradar Group AG is rated a strong buy with a $20 price target, implying about 50% upside from current levels despite recent stock price decline from $18.57. The company reported 19% year-over-year revenue growth in Q2, supported by strong cash flow and a solid balance sheet. Speculation about integration with Meta's Muse has increased options activity but is not factored into the valuation. Key risks include potential US growth stabilization and management's ability to maintain guidance, with any forecast cuts or EBITDA misses possibly pressuring the stock's value.
Sportradar's recent developments provide context for technology sector trends on Pluang. Of 150 priced US tech stocks today, 21 rose and 116 fell as of Sep 28, 2026 18:51 WIB. Notable movers include FIRY at USD 12.99 with a 4.59% gain and NTES at USD 120.57 with a 4.47% increase.
Grail's stock surged 55% in one week following a positive FDA advisory committee vote on its Galleri multi-cancer early detection test, which was deemed safe and beneficial. Analyst Kyle Mikson raised the price target from $80 to $150, reflecting str...
Roblox stock fell 6% following Jefferies' downgrade to Underperform and a price target cut to $38, citing concerns over overly optimistic bookings outlook and slower user growth in the US and Canada. This downgrade contrasts with steady performance i...
Geely Holding Group has acquired a 30% stake in Nio Power, the battery swapping and charging unit of Nio, valuing the business at about RMB16 billion. This investment marks a significant external validation of Nio's battery swapping network, a key as...
CoreWeave reported strong Q2 results with significant scale and margin improvements, supported by a $104.2 billion backlog driven by demand from hyperscalers exceeding supply. The company raised its 2026 revenue guidance to $12.4–$13.2 billion, expec...
Tiziana Life Sciences has dosed the first three patients in a Phase 2a trial testing foralumab, a nasal spray antibody, for treating early-stage ALS. The Healey ALS MyMatch BANYAN trial will enroll 44 patients to evaluate safety, tolerability, and im...
